Fundraising Fox

Glycomine

San Francisco, US · Founded 2014 · 11 known investors

Find your way into Glycomine

Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.

Biotech

Founders & leadership

Glycomine was founded in 2014 by Agnes Rafalko.

AR
Agnes RafalkoFounder

Board

PCPeter C.M. McWilliams
Peter C.M. McWilliamsBoard directorVenture Partner at Sanderling Ventures
GCGiacomo Chiesi
Giacomo ChiesiinBoard directorManaging Partner at Chiesi Ventures
CS
Christopher StarrBoard director

Investors · 11

Advent Life SciencesLondon
Chiesi VenturesBoston · $5M
CTI Life Sciences Fund L.P.Montréal
Remiges Ventures, Inc.Seattle
RiverVest Venture PartnersSt. Louis · $500K – $3M
Sanderling VenturesSan Mateo · $50K – $1M
Sanofi VenturesCambridge · $5M
AbingworthreportedLondon · $15M – $30M
abrdn plcreportedEdinburgh
Mission BiocapitalreportedSan Francisco · $500K
Novo HoldingsreportedCopenhagen · $1.1M – $54M

Funding

SEC filings, press & company announcements

$234.9M disclosed across 3 of 4 rounds · 2016–2025

▶$4.9MraisedNov 2016 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher StarrDirector
  • Peter C.M. McWilliamsDirector
  • Agnes RafalkoExecutive Officer, Director
  • Giacomo ChiesiDirector
Offering amount
$12.6M
Amount sold
$4.9M
Minimum investment
$10K
First sale
Oct 2016
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Startup Glycomine raises $115M to push rare disease drug deeper into testing | BioPharma Divebiopharmadive.com · Apr 2025Glycomine Gets $115M Series C for Rare Disease, Aims for Phase II Launch Mid-Year - BioSpacebiospace.com · Apr 2025Glycomine Raises $115 Million to Advance Therapy for Metabolic Disorder - Global Genesglobalgenes.org · Apr 2025Glycomine Raises $115M in Series C Financingfinsmes.com · Apr 2025Glycomine Raises $35 Million to Advance Novel Treatment for Rare Glycosylation Disease - Global Genesglobalgenes.org · Jun 2021Glycomine nets $33 million, plus more top funding news for San Francisco-based companieshoodline.com · Aug 2019

Frequently asked questions

What does Glycomine do?
Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.
Who founded Glycomine?
Glycomine was founded by Agnes Rafalko in 2014.
Who are Glycomine's investors?
Glycomine's investors include Advent Life Sciences, Chiesi Ventures, CTI Life Sciences Fund L.P., Remiges Ventures, Inc., RiverVest Venture Partners, Sanderling Ventures, Sanofi Ventures, Abingworth and 3 more.
How much funding has Glycomine raised?
Glycomine has disclosed $234.9M raised across 3 of its 4 known rounds.
Where is Glycomine headquartered?
Glycomine is headquartered in San Francisco, US.